Today: 7 February 2026
Subscribe

Moderna stock jumps 12% after $1.9 billion 2025 sales view — what investors watch next

Moderna stock jumps 12% after $1.9 billion 2025 sales view — what investors watch next

New York, January 13, 2026, 11:31 EST — Regular session Moderna shares were up $3.97, or 11.7%, at $37.81 by late morning in New York, lifting the vaccine maker to one of the stronger movers in biotech trading. The bounce comes as investors try to pin down what “post-pandemic Moderna” looks like — smaller, more volatile, and still dependent on seasonal vaccine demand that can shift fast. The company’s early look at 2025 is being read as a test of whether the slide has finally slowed. Moderna said it expects about $1.9 billion in 2025 sales, near the top end
13 January 2026
····
Bank of America stock slips as Trump credit-card cap clouds BAC earnings

Bank of America stock slips as Trump credit-card cap clouds BAC earnings

New York, Jan 13, 2026, 11:55 AM EST — Regular session Shares of Bank of America Corp (BAC) dropped 0.9% to $54.72 in late-morning trading Tuesday in New York, as investors weighed a proposed cap on credit-card interest rates. The stock reacted after U.S. consumer prices rose 0.3% in December, matching expectations, with a 2.7% increase year-on-year. Core CPI, excluding food and energy, climbed 0.2% monthly and 2.6% annually. The Fed is widely expected to hold its policy rate steady at the Jan. 27-28 meeting, the report said. “The recent run of figures suggests inflation has peaked,” said Michael Pearce,
13 January 2026
····
Strategy (MSTR) stock jumps as $1.25 billion Bitcoin buy and insider purchase hit the tape

Strategy (MSTR) stock jumps as $1.25 billion Bitcoin buy and insider purchase hit the tape

New York, January 13, 2026, 11:37 EST — Regular session Shares of Strategy Inc climbed roughly 3.6% to $168.01 Tuesday morning, buoyed by a 1.6% rise in bitcoin following the company’s announcement of a $1.25 billion crypto purchase. The firm sold about 6.83 million shares and 1.19 million preferred STRC shares, netting approximately $1.25 billion. It deployed those funds to acquire 13,627 bitcoin, paying an average of $91,519 per coin, boosting its total holdings to 687,410. (SEC) This filing is crucial since Strategy’s stock still acts as a bitcoin proxy, but with a twist: it keeps tapping the equity market
13 January 2026
·····
IREN Limited stock nudges higher after H.C. Wainwright upgrade as bitcoin firms

IREN Limited stock nudges higher after H.C. Wainwright upgrade as bitcoin firms

New York, Jan 13, 2026, 11:36 ET — Regular session IREN Limited shares ticked up roughly 1% to $50.82 around midday Tuesday. The boost came after H.C. Wainwright raised its rating on the Nasdaq-listed firm to “buy,” attaching an $80 price target. (MarketBeat) Bitcoin climbed roughly 1.5% to $93,434, while mining-related stocks like Marathon Digital, Riot Platforms, and CleanSpark also saw gains. The upgrade is significant since IREN now stands as a high-beta play linked to two volatile arenas: crypto prices and the race for AI computing power. When risk appetite changes, the stock can swing sharply. Investors are also
13 January 2026
·····
Eli Lilly stock (LLY) edges up as FDA clears GLP-1 label cloud; $150 pill launch looms

Eli Lilly stock (LLY) edges up as FDA clears GLP-1 label cloud; $150 pill launch looms

New York, Jan 13, 2026, 11:51 EST — Regular session Shares of Eli Lilly and Company inched up 0.2% to $1,083.63 on Tuesday, fluctuating between $1,070 and $1,090 as roughly 736,000 shares exchanged hands. The move followed the U.S. Food and Drug Administration’s request that drugmakers strip suicide-related warnings from labels on GLP-1 weight-loss medications, including Lilly’s Zepbound and Novo Nordisk’s Wegovy. (Reuters) The request matters because safety language on labels can influence how quickly doctors prescribe and how confident insurers feel about coverage. In a market already clogged with supply and demand chatter, even minor shifts in perceived risk
13 January 2026
····
TTM Technologies stock surges nearly 20% as TTMI draws fresh attention at Needham Growth Conference

TTM Technologies stock surges nearly 20% as TTMI draws fresh attention at Needham Growth Conference

New York, Jan 13, 2026, 11:23 EST — Regular session underway TTM Technologies shares surged roughly 19% Tuesday, hitting $92.84 late morning. The circuit-board manufacturer pushed higher on strong volume, continuing its recent rally. Investors zeroed in on TTM’s upcoming slot at the Needham Growth Conference in New York. CEO Edwin Roks and CFO Dan Boehle were set to speak early Tuesday. (TTM Technologies, Inc.) This year’s Needham event spans several days, combining virtual and in-person sessions and attracting hundreds of companies. This format tends to funnel quick capital into high-momentum stocks. (Needham & Company) TTM is often described as
13 January 2026
·····
AppLovin stock rises as Wall Street resets targets — what traders are watching next

AppLovin stock rises as Wall Street resets targets — what traders are watching next

New York, January 13, 2026, 11:12 AM (ET) — Market open AppLovin shares rose roughly 0.5% Tuesday, recovering after a volatile start as investors digested new price targets from brokers on the ad-tech firm. Timing is crucial. Since the start of the year, AppLovin has behaved like a momentum play, and even slight shifts in sell-side sentiment can sway the stock when positioning is tight and expectations run high. At 11:12 a.m. ET, the stock changed hands at $662.24, having fluctuated from a low of $643.00 to a high of $666.57. The wider market edged lower, with the S&P 500
13 January 2026
·····
UiPath stock slides after CEO Daniel Dines sells shares — what PATH investors watch next

UiPath stock slides after CEO Daniel Dines sells shares — what PATH investors watch next

New York, Jan 13, 2026, 11:14 EST — Regular session Shares of UiPath Inc dropped roughly 7.7% to $15.92 on Tuesday following a regulatory filing that revealed new insider selling at the automation software company. The stock had climbed to $17.63 earlier in the day. This shift is crucial as UiPath returns to the spotlight while investors assess enterprise spending on automation and AI. With the fiscal quarter closing, traders latch onto any sign of subscription growth—or its absence. Insider sales happen regularly, but they tend to draw notice when a stock is volatile and lacks an earnings report to
13 January 2026
·····
Netflix stock barely moves as Paramount lawsuit intensifies fight over Warner deal

Netflix stock barely moves as Paramount lawsuit intensifies fight over Warner deal

New York, January 13, 2026, 11:08 (ET) — Regular session Netflix, Inc. shares were little changed on Tuesday after Paramount Skydance sued Warner Bros Discovery and said it would nominate directors in a bid to block Warner’s planned deal with Netflix, Reuters reported. Paramount is pitching a $30-per-share all-cash tender offer — an offer to buy stock directly from shareholders — that expires on Jan. 21, versus Netflix’s $82.7 billion cash-and-stock agreement valued at $27.75 per share for Warner’s studios and streaming assets. Netflix was up 0.03% at $89.44 in late-morning trade, while Warner fell 0.3% and Paramount Skydance slipped
13 January 2026
·······
Intel stock pops after KeyBanc upgrade, $60 target as AI server demand tightens

Intel stock pops after KeyBanc upgrade, $60 target as AI server demand tightens

NEW YORK, January 13, 2026, 11:14 EST Intel (INTC.O) shares surged roughly 6% Tuesday following KeyBanc Capital Markets’ upgrade to “overweight,” signaling expectations for the stock to outperform. The firm also raised its price target to $60. Intel’s stock climbed 6.4% to $46.88 in late morning deals. (Barron’s) The call comes as Intel is already on a hot streak, soaring 27% this year after an 84% jump in 2025, with investors hunting for the next AI-driven winners. KeyBanc’s John Vinh described Intel’s AI efforts as still “nascent,” but noted the company is gaining traction thanks to growing data-center investments. (MarketWatch)
13 January 2026
·····
SMCI stock slides after Goldman starts Super Micro at Sell and flags margin downside

SMCI stock slides after Goldman starts Super Micro at Sell and flags margin downside

New York, January 13, 2026, 11:07 EST Shares of Super Micro Computer (SMCI) fell on Tuesday after Goldman Sachs assumed coverage of the AI-server maker with a Sell rating, warning profit margins could weaken further even as demand for artificial intelligence (AI) hardware stays strong. The stock was down about 6.0% at $28.31 as of 10:51 a.m. EST. (Investing.com) The call lands at a touchy moment for Super Micro, which sits in the middle of the AI buildout but is being judged less on how fast it ships boxes and more on what it keeps after costs. For a stock
13 January 2026
·····
Intel stock jumps near 6% on KeyBanc upgrade — and a filing shows a big holder cut back

Intel stock jumps near 6% on KeyBanc upgrade — and a filing shows a big holder cut back

NEW YORK, Jan 13, 2026, 11:07 EST Intel shares climbed 5.9% to $46.64 by 11:07 a.m. EST Tuesday, on roughly 69 million shares traded. Advanced Micro Devices also jumped, up 5.0% in early trading. Intel’s surge is significant because its strong start to the year has morphed into a showdown between optimism over “AI spillover” and lingering doubts about its execution. Server demand linked to AI investments has emerged as a key measure, with traders scrutinizing each data point as a verdict on the company’s prospects. KeyBanc’s John Vinh raised Intel to “Overweight” from “Sector Weight,” upping his price target
13 January 2026
······
1 … 689 690 691 692 693 … 2,711

Stock Market Today

GSK share price set for Monday watch after EU clears Nucala COPD use

GSK share price set for Monday watch after EU clears Nucala COPD use

7 February 2026
GSK shares closed Friday up 0.83% at a 52-week high after the EU approved Nucala for certain uncontrolled COPD patients. Insider filings showed chairman Jonathan Symonds bought 2,500 shares while executive David Redfern sold 100,000. The FTSE 100 rose 0.6%. Broker ratings on GSK remained mixed.
Go toTop